You are here

The Immune Deficiency Foundation is currently exploring opportunities within the Food and Drug Administration’s (FDA) Patient Focused Drug Development (PFDD) program for potential applicability to efforts to advance therapies for primary immunodeficiency diseases (PI).

PFDD was created to enhance the role and involvement of the patient in the therapy development process to, ultimately, support development of therapies and treatments that don’t exist today. The FDA seeks to expand its understanding of specific diseases by hosting voice of the patient meetings to get the perspective of impacted patients. IDF is currently exploring areas where the PI community perspective is needed to help with the development of new treatments including gene therapy to treat a variety of PI conditions.